ZenenBio is engaged in industrial printing and nameplate manufacturing, surface treatment of materials, and electronic component manufacturing. In 2017, it acquired Gonggam ENT Co., Ltd., and in 2018, APR Lab Co., Ltd. Last year, it merged APR Lab Co., Ltd. on a small scale and is also promoting new businesses such as bio and environmental projects.
ZenenBio has secured personnel capable not only of developing xenogeneic organ products but also performing transplantation. The company is pushing forward to expand into medical institutions that can carry out surgeries. Currently, there are no competitors in Korea capable of performing xenogeneic organ transplantation surgery, giving ZenenBio a competitive edge to dominate the market.
Patent attorney Um Jeong-han of BLT Patent Law Office reviewed ZenenBio’s patent and trademark application status.
Listed companies on the domestic stock market disclose patent acquisition information through the Financial Supervisory Service’s electronic disclosure system. However, many stock investors tend to overlook patent disclosures.
Not only patents but also trademark registrations indicate the future direction of listed companies, making them one of the important indicators for assessing future corporate value. Some patent disclosures even act as direct triggers for stock price increases.
It is not easy for general investors to understand the impact on companies through patent disclosures or to check trademark application statuses one by one. Asia Economy, together with patent attorney Um Jeong-han of BLT Patent Law Office, is reviewing the patent and trademark application status of listed companies through the 'Express Train'.
'Express Train' is an abbreviation for a broadcast that diligently searches for stocks soaring due to patents.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
